South Korea Dry Age-Related Macular Degeneration (AMD) Market Research Report By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Users (hospitals clinics, diagnostic centers, academic research institutes) -Forecast to 2035
The South Korea Dry Age-Related Macular Degeneration market is projected to grow significantly from 1250 USD Million in 2024 to 2750 USD Million by 2035.
South Korea Dry Age-Related Macular Degeneration (AMD) Key Trends and Highlights
| 2024 Market Size | 1250 (USD Million) |
| 2035 Market Size | 2750 (USD Million) |
| CAGR (2025 - 2035) | 7.43% |
Bayer, Zeiss, Hector Pharmaceuticals, Roche, VIVUS, Ophthotech, Alcon, Pfizer, Kowa Company, Novartis, Santen Pharmaceutical, HoffmannLa Roche, Eyenovia, Regeneron Pharmaceuticals
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry
The South Korea Dry Age-Related Macular Degeneration (AMD) market is experiencing noteworthy trends driven by the increasing aging population in the country. With a significant portion of its population over the age of 65, there is a growing prevalence of AMD in South Korea, thereby creating a heightened demand for effective treatment options and healthcare solutions.
Government initiatives promoting eye health awareness, along with advancements in diagnostic technologies, are also key market drivers contributing to the growth of this sector. This focus on healthcare is visible in various public health campaigns organized by the Ministry of Health and Welfare, which strive to educate the population about the importance of early detection and management of AMD.
Innovative therapy fields like gene therapy and new pharmacological approaches are making South Korea increasingly invest in R&D, which creates business opportunities for foreign markets. Moreover, the strong focus on biotechnological and pharmaceutical innovation presents a window of opportunities for emerging firms to seek alliances with large companies so as to hasten the development and marketing of their products.
In addition, there exists an opportunity to improve telemedicine monitoring and management of AMD and enhance patient outcomes as South Korea further invests in healthcare technology. There is also a recent trend of more collaboration between educational institutions and healthcare providers to facilitate research activities directed toward AMD treatment.
Advanced clinical trials are becoming more common, and there is a concerted effort to integrate artificial intelligence into diagnostic processes, streamlining early detection methods. Additionally, a growing awareness among consumers about the significance of nutrition and lifestyle modifications in managing AMD is shaping market dynamics, encouraging thorough discussions on the potential of various health supplements and dietary plans aimed at slowing disease progression.
Overall, these combined elements signify a proactive approach to addressing AMD within South Korea's healthcare landscape.
The increasing incidence of dry age-related macular degeneration (AMD) among the aging population in South Korea is a primary driver of the Global South Korea Dry Age-Related Macular Degeneration (AMD) Market Industry. As the population ages, the number of individuals affected by AMD is expected to rise significantly. By 2024, the market is projected to reach 1250 USD Million, reflecting the urgent need for effective treatment options. This trend is likely to continue, with projections indicating that by 2035, the market could expand to 2750 USD Million. Such growth underscores the importance of addressing AMD in the healthcare agenda.
The South Korea Dry Age-Related Macular Degeneration (AMD) Market shows a structured segmentation based on the stage of the disease, which includes early, intermediate, and late age-related macular degeneration. Each of these stages presents distinct clinical features and treatment strategies, making them critical in understanding the overall landscape of the market.
The early stage often comes with mild symptoms, and while it may go unnoticed, it serves a pivotal role in informing healthcare strategies aimed at early intervention. Intermediate age-related macular degeneration is characterized by more pronounced symptoms and visual disturbances, necessitating a greater focus on patient management to prevent progression to late-stage disease.
This stage is significant in terms of patient care as it often represents a transitional phase where intervention can be most effective, thus helping to maintain the quality of life for patients. Late age-related macular degeneration is the most severe form, leading to substantial vision loss and presenting considerable challenges in terms of treatment and rehabilitation.
The Age Group segmentation of the South Korea Dry Age-Related Macular Degeneration (AMD) Market highlights the increasing prevalence of AMD among the older population, particularly those above 60 years. This age group acts as a significant driver for the market due to the higher risks associated with aging and vision impairment.
The population aged above 75 years often represents a substantial portion of AMD cases, experiencing a greater burden of vision-related issues that necessitate advanced care and treatments. Additionally, individuals aged above 40 years are becoming increasingly aware of AMD, leading to earlier screenings and interventions, which are pivotal in managing the condition effectively.
With South Korea's aging demographic, the demand for tailored healthcare solutions is growing, positioning this market segment for considerable development. The government’s initiatives focusing on elderly health are further driving awareness and encouraging better management practices. The interplay between the rising elderly population and heightened awareness around eye health creates both challenges and opportunities within the South Korea Dry Age-Related Macular Degeneration (AMD) Market, fundamentally influencing trends, healthcare policies, and market dynamics in the region.
The South Korea Dry Age-Related Macular Degeneration (AMD) Market is characterized by extensive developments in the Diagnosis and Treatment segment, which together are essential in improving patient outcomes. The treatment part is crucial as it typically involves therapies that slow disease progression and manage symptoms, helping to preserve vision for a growing elderly population that is particularly susceptible to AMD.
Meanwhile, advancements in diagnostic techniques enhance early detection, thereby enabling timely intervention. As the prevalence of dry AMD rises in South Korea, driven by an aging demographic, these segments are becoming increasingly significant within the overall market. Notably, technological innovations such as advanced imaging techniques are transforming the diagnostic landscape, facilitating quicker and more accurate diagnoses.
Government initiatives aimed at increasing awareness and providing healthcare access further bolster the market, creating substantial opportunities for growth. Moreover, the growing focus on personalized medicine in the treatment segment signals a shift toward more effective and tailored therapies for patients, shaping the future landscape of the South Korea Dry Age-Related Macular Degeneration (AMD) Market.
The South Korea Dry Age-Related Macular Degeneration (AMD) Market is experiencing notable growth, particularly in the Route of Administration segment, which plays a crucial role in treatment efficacy. Within this segment, oral formulations and injectables are key methods for delivering therapeutic agents.
Oral administration often offers patient convenience and adherence, making it an attractive option for many patients dealing with chronic conditions like AMD. In contrast, injectables can provide faster therapeutic effects and are essential for delivering specific treatments that require direct action within the eye, highlighting their significance in managing advanced disease stages.
As the South Korean population ages and the prevalence of AMD increases, the demand for effective treatment delivery continues to rise. The government's focus on healthcare improvements and advancements in drug formulations are likely to drive the market, ensuring that both methods capture significant shares of the South Korea Dry Age-Related Macular Degeneration (AMD) Market revenue.
The South Korea Dry Age-Related Macular Degeneration (AMD) Market is significantly influenced by its End Users, which comprise hospitals clinics, diagnostic centers, and academic research institutes. Hospitals clinics lead this sector as they play a crucial role in diagnosing and treating AMD, ensuring patients receive timely interventions.
Diagnostic centers contribute significantly by providing essential testing services, which are required for accurate diagnosis and management of the condition. The growing significance of these centers is underscored by advancements in diagnostic technologies that enhance the detection rates of AMD.
Academic research institutes are pivotal as they drive innovation through research and development efforts, leading to new treatment modalities and therapeutic approaches, thereby improving patient outcomes. The combined efforts of these End Users are essential in addressing AMD in South Korea, especially considering the demographic shift towards an aging population and the increasing prevalence of eye-related disorders.
Get more detailed insights about South Korea Dry Age Related Macular Degeneration Market Request Free Sample
The South Korea Dry Age-Related Macular Degeneration (AMD) Market is a dynamic and rapidly evolving space characterized by a growing emphasis on advanced therapeutic solutions and innovative technologies aimed at addressing the needs of patients affected by AMD. This segment faces varied competition from pharmaceutical firms, medical device manufacturers, and biotechnology companies, each vying for a larger share of the market. The increasing prevalence of AMD due to the aging population combined with rising awareness and screening initiatives create a fertile ground for both established and emerging players. Competitive insights reveal that firms are leveraging strategic alliances, mergers, and product innovations to enhance their market positions. Key indicators of competitiveness in this market include technological advancements, product pipeline progress, regulatory compliance, and overall patient satisfaction. Bayer has established a significant presence in the South Korea Dry Age-Related Macular Degeneration (AMD) Market, driven by its robust portfolio and strong reputation for innovation. The company's strengths lie in its comprehensive approach to AMD, which includes not only pharmaceutical treatments but also extensive research and development efforts aimed at discovering new solutions. Bayer's marketing and distribution strategies are well-tailored for the South Korean healthcare landscape, where they effectively communicate the advantages of their AMD therapies to both healthcare providers and patients. Their ability to engage in partnerships with local healthcare entities further enhances their market presence, solidifying Bayer's position as a trusted player in providing medications that cater to the specific needs of AMD sufferers within the region. On the other hand, Zeiss occupies a unique niche within the South Korea Dry Age-Related Macular Degeneration (AMD) Market by focusing on advanced diagnostic equipment and optical solutions essential for AMD diagnosis and monitoring. The company is recognized for its precision in ophthalmic technologies, which includes state-of-the-art imaging systems that enhance early detection and treatment planning for AMD. Zeiss capitalizes on its innovative technology and strong brand reputation, ensuring it maintains a formidable market presence in South Korea. Their key products include high-resolution imaging devices and diagnostic tools that provide comprehensive assessments of retinal health. Moreover, Zeiss's strategic collaborations and potential mergers and acquisitions bolster its capabilities in delivering advanced solutions tailored specifically for AMD care, thereby reinforcing its commitment to improving patient outcomes and staying ahead in a competitive market.
The South Korea Dry Age-Related Macular Degeneration (AMD) Market has seen notable developments in recent months. In July 2023, Bayer announced advancements in its therapeutic pipeline targeting dry AMD, aiming to enhance treatment efficacy and patient outcomes.
Zeiss has been actively integrating innovative imaging technologies in its diagnostic tools, further augmenting early detection rates of AMD, which has raised awareness around the disease. Meanwhile, Regeneron Pharmaceuticals is experiencing growth in its market valuation, driven by the ongoing demand for its therapies, reflecting positively on the AMD sector in South Korea.
Recent collaborations have hinted at potential mergers in the market, particularly between companies like Ophthotech and significant investment firms interested in AMD treatment advancements. In September 2023, HoffmannLa Roche revealed ongoing clinical trials to evaluate new treatment protocols, indicating a commitment to address unmet medical needs.
Growth in the South Korean aging population is also influencing trends, as the government has increased funding for ophthalmic research, thereby supporting ongoing innovations. The landscape continues to evolve as companies like Alcon and Novartis explore new partnerships and approaches to AMD, underscoring a dynamic market environment.
The South Korea Dry Age-Related Macular Degeneration (AMD) Market is projected to grow at a 7.43% CAGR from 2025 to 2035, driven by increasing aging population and advancements in treatment technologies.
New opportunities lie in:
By 2035, the South Korea Dry AMD Market is expected to exhibit robust growth, reflecting advancements in care and increasing patient demand.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 110.0(USD Million) |
| MARKET SIZE 2024 | 120.0(USD Million) |
| MARKET SIZE 2035 | 320.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.326% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Bayer, Zeiss, Hector Pharmaceuticals, Roche, VIVUS, Ophthotech, Alcon, Pfizer, Kowa Company, Novartis, Santen Pharmaceutical, HoffmannLa Roche, Eyenovia, Regeneron Pharmaceuticals |
| SEGMENTS COVERED | Stage, Age Group, Diagnosis and Treatment, Route of Administration, End Users |
| KEY MARKET OPPORTUNITIES | Aging population increasing prevalence, Advancements in treatment technologies, Growing awareness and education, Development of preventive therapies, Enhanced diagnostic tools and services |
| KEY MARKET DYNAMICS | Increasing aging population, Growing prevalence of AMD, Advancements in treatment options, Rising awareness of eye health, Government healthcare initiatives |
| COUNTRIES COVERED | South Korea |
Kindly complete the form below to receive a free sample of this Report
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
